Chest
-
Infectious Diseases CasesSESSION TYPE: Case ReportsPRESENTED ON: Saturday, March 22, 2014 at 04:15 PM - 05:15 PMINTRODUCTION: Daptomycin is a semisynthetic lipopeptide antibiotic, the first to be marketed, used to treat gram-positive bacterial infections, specifically skin and soft tissue infections or Staphylococcus aureus bacteremia and right-sided endocarditis. Although it cannot be used in the treatment of pneumonia, due to inactivation by pulmonary surfactant, in isolated cases it has been associated with life-threatening eosinophilic pneumonia. The majority of reported cases have high levels of serum eosinophilia. We report a case of daptomycin induced eosinophilic pneumonia without elevated serum eosinophilia. ⋯ In those patients whom daptomycin is used, we must be aware of potentially life threatening daptomycin induced lung disease, even in the absence of eosinophilia. Immediate recognition is vital as discontinuation of the offending agent alone can quickly resolve the lung disease.Reference #1: Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports. Kim PW, et al. Drug Saf. 2012 Jun 1;35Reference #2: Package insert. Cubicin (daptomycin). Lexington, MA: Cubist Pharmaceuticals. Aug 2010DISCLOSURE: The following authors have nothing to disclose: Anita Rajagopal, Edward Mintz, Lindsey ReeseNo Product/Research Disclosure Information.
-
Infectious Disease Case Reports Posters IIISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: The most common cause of granulomatous inflammation of lung in India is tuberculosis (TB), other etiologies need to be considered if the clinical scenario is not consistent with TB. We present an unusual cause of granuloma, which remained elusive for over two and half years. ⋯ Chronic aspergillosis presenting as lung and kidney mass in apparently immunocompetent host has been rarely reported. Fungal infections need to be considered as a cause of granulomatous inflammation even in tuberculosis endemic countries.Reference #1: Kang EY, Kim DH etal. Pulmonary aspergillosis in immunocompetent hosts without underlying lesions of the lung: radiologic and pathologic findings.Am J Roentgenol. 2002 Jun;178(6):1395-9.Reference #2: Yoon SH, Park CM et al. Pulmonary aspergillosis in immunocompetent patients without air-meniscus sign and underlying lung disease: CT findings and histopathologic features. Acta Radiol. 2011 Sep 1;52(7):756-61.Reference #3: Myerson DA, Rosenfield AT. Renal aspergillosis: a report of two cases.J Can Assoc Radiol. 1977 Sep;28(3):214-6DISCLOSURE: The following authors have nothing to disclose: Vishwanath Gella, Srinivas Upendra, Adarsh BarwadNo Product/Research Disclosure Information.
-
Lung Cancer Posters ISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Solitary pulmonary nodule (SPN) is increasingly detected on chest imaging andposes a challenge to clinicians because the differential diagnosis is extensive. This study was aimed to reveal the histologic spectrum of resected SPNs. ⋯ The following authors have nothing to disclose: Yiliang Zhang, Yuan Li, Ting Ye, Yang Zhang, Yihua Sun, Jiaqing Xiang, Yawei Zhang, Hecheng Li, Lei Shen, Haiquan ChenNo Product/Research Disclosure Information.
-
Thoracic Surgery PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To delineate a successful approach to treating synchronous primary lung cancers arising simultaneously with one primary in each lung. The primary which appears to be more advanced clinically is resected first. The second is resected as soon as possible after the patient has rcovered adequately from the first procedure. ⋯ The following authors have nothing to disclose: Geoffrey Graeber, Syed Quadri, Karl UyNo Product/Research Disclosure Information.
-
Tobacco Cessation and Prevention PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To analyze and validate 2 month treatment programs, as well as the real dose and time decided by the patient regarding what is recommended and its influence on the tobacco cessation rate. ⋯ The following authors have nothing to disclose: Ana Gomez-Bastero, Concepcion Romero, Estefania Luque, Virginia Almadana, Soledad Montserrat, Teodoro MontemayorNo Product/Research Disclosure Information.